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G R A P H I C A L A B S T R A C TA B S T R A C T
Recently chimeric inﬂuenza haemagglutinins (cHAs) have been generated as potential ‘universal’ vaccination
antigens and as tools to identify HA stalk-directed antibodies via their use as antigens in ELISA, and virus or
pseudotype-based neutralization assays. The original methods [1,2] used for their generation require the
ampliﬁcation of regions of interest (head and stalk) using primers containing SapI sites and subsequent cloning
into pDZ plasmid. This requires precise primer design, checking for the absence of SapI sites in the sequence of
interest, andmulti-segment ligation. As an alternative strategy we have developed and optimized a new protocol
for assembling the cHA by exploiting Gibson Assembly.
 This method also requires precise primer design, but it is rapid and methodologically simple to perform. We
have evaluated that using this method it is possible to construct a cHA encoding DNA in less than a week.
 Additional weeks are however necessary to optimize the production of pseudotyped lentiviral particles and to
perform neutralization assays using them as surrogate antigens.ht
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12 F. Ferrara, N. Temperton /MethodsX 4 (2017) 11–24 In comparison to the original protocols, we have also observed that performing parallel neutralization assays
using pseudotypes harbouring the two parental HAs, permits effective delineation between stalk and head
antibody responses in the samples tested.© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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 Haemagglutinin sequences (nucleotide and amino acid)
 Q51 High-Fidelity DNA Polymerase (New England Biolabs, cat. # M0491S)
 DreamTaq Green PCR Master Mix (Thermo Fisher Scientiﬁc, cat. # K1081 or K1082) (OPTIONAL)
 Gibson Assembly Cloning kit (New England Biolabs, cat. # E5510).
 FastDigest DpnI (Thermo Fisher Scientiﬁc, cat. # FD1703)
 FastDigest or conventional Restriction Enzymes (Thermo Fisher Scientiﬁc)
 RNAse/DNase free water
 Agarose
 Nucleic Acid Gel Stain
 Tris base, acetic acid and EDTA (TAE) Buffer
 GeneRulerTM 1kb DNA Ladder Mix (Thermo Fisher Scientiﬁc, cat. # SM0314) or similar DNA Ladder
 Loading dye (Thermo Fisher Scientiﬁc, cat. # R0611) or similar loading dye
 QIAquick PCR Puriﬁcation Kit (QIAGEN, cat. # 28104) or similar kits (OPTIONAL)
 QIAprep Spin Miniprep Kit (QIAGEN, cat. # 27104) or similar kits
 Luria Bertani (LB) agar plates with antibiotics appropriate to the plasmid used
 LB broth with antibiotics appropriate to the plasmid used
 Thermocycler
 Water bath or heating block
 Incubator at 37 C
 Gel electrophoresis system
 Microwave (to dissolve agarose gel)
 Bioinformatics software for DNA and protein sequence and structure analysis
Cloning the chimeric haemagglutinin
Selection of haemagglutinin parental strains
Before proceeding to clone the chimeric HA (cHA), it is necessary to identify which HA subtypes/
strainswill be used to generate the cHA. There are different factors to take into consideration. Firstly, it
is important to identify the ﬁnal purpose of the project for which cHA are required. For example if
human stalk-directed antibody responses are to be detected it is more appropriate to choose the head
region of an HA subtype that is less related to circulating human inﬂuenza strains (i.e. H1 and H3) or
other to strains that have been shown to infect humans (e.g. H5 and H7), such as H11 or H16.
Furthermore, depending on the experimental requirements, selecting for the stalk an HA that is
currently, or has previously circulated in humansmay also be appropriate. This is extremely important
since it permits the minimizing of detection of cross-reactive antibodies against the head, and the
maximising of the identiﬁcation of stalk-directed responses.
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Two cysteines, Cys52 and Cys277 represent the hinge between the HA head and stalk regions.
These two cysteines can thus be exploited using DNA recombinant technology to exchange the HA
head of one virus with the HA head of another inﬂuenza strain creating cHA [2] (Fig. 1A). The protocol
described here (Fig. 1B) is based on the ampliﬁcation of plasmid DNA to create two linearized DNA
fragments: The ﬁrst fragment (around 700bp depending on the inﬂuenza strain used)will correspond to the HA
head region, it will be ampliﬁed from one of the HA-encoding plasmids (parental 1) and it will
contain 50 and 30 additional region overlapping with the stalk of the other HA; The second fragment comprises the expression vector and the stalk region (length depending on the
inﬂuenza strain used, around 1000bp, and on the expression vector used), and will be ampliﬁed
from the other HA-encoding plasmid (parental 2).
Gibson Assembly is then used to combine these two fragments. The Gibson Assemblymethodology
permits the rapid assembly of multiple overlapping DNA fragments through a reaction inwhich three
different enzymes are used at the same time: an exonuclease to create 30 overhangs, a polymerase to
ﬁll gaps, and DNA ligase to close the nicks in the assembled DNA [3].
Step 1: Primer design
New England Biolabs, who distribute the Gibson Assembly kit used in this method, offers on its
website a free tool, NEBuilder Assembly Tool, that permits in-silico assembly of the DNA sequence of
interest (e.g. the cHA). This web tool additionally designs the primers that should be employed to
generate the fragment of interest (HA head and vector plus HA stalk) that will be assembled.
Below we report step-by-step the procedure used to design the HA primer using this web tool.i Align using Jalview [4] or equivalent software, the amino acid sequences of the two HAs.
ii Identify Cys52 and Cys277 in the two sequences. This step should be performed carefully since the
numbering reported corresponds to the H3 numbering system and may not correspond to the
numbering of the HAs usediii After identiﬁcation of the Cys, if possible, check on the structure of the HA subtypes chosen such
that the Cys identiﬁed correspond to the hinge Cys52 and Cys277. These structures, if available can
be downloaded from the RCSB Protein Data Bank database (www.rcsb.org) [5]. We use Swiss PDB-
Viewer [6] to visualize them but it is possible to use other protein structure visualization tools (e.g.
Jalview, UCSF Chimera, RasMol, Jmol, etc.).iv Assemble the predicted amino acid sequence of the cHA by removing the amino acid sequence
corresponding to the original HA head (between the two cysteines) and inserting in the amino acid
sequence of the other HA. This chimeric sequence will be used to check the ﬁnal assembly.v Now that the cysteines have been identiﬁed it is necessary to identify the nucleotides that encode
for them. Software such as DNADynamo (BlueTractorSoftware), or BioEdit can be useful for this
purpose.
a Once the nucleotides that encode the cysteines of the HAused for the stalk (parental 2) have been
identiﬁed note down the number of the last nucleotide encoding Cys52 and the number of the
ﬁrst nucleotide encoding Cys277.Once the nucleotides that encode the cysteines of the HA used for the head (parental 1) have been[43_TD$DIFF]vi
identiﬁed, copy the sequence between the last nucleotide encoding Cys52 and the number of the
ﬁrst nucleotide encoding Cys277 in a new sequence text ﬁle that you will conserve.[44_TD$DIFF] Open the NEBuilder Assembly Tool (http://nebuilder.neb.com/)
[45_TD$DIFF] In “set preferences” select E5510 Gibson Assembly Cloning kit and check that the other preferences
are set as shown in Fig. 2.
[46_TD$DIFF] Select “Build Construct” and press “ADD FRAGMENT”.
[(Fig._1)TD$FIG]
Fig. 1. Chimeric haemagglutinin and cloning strategy to generate it.
A. Structure of inﬂuenza haemagglutinin polypeptide highlighting the cleavage site, the head, the stalk, Cys52 and Cys277 that
need to be identiﬁed in the HA sequences to proceed with cHA cloning; B. Cloning strategy used to build cHA using Gibson
assembly method: after primer design the HA head and the HA stalk with the plasmid backbone are ampliﬁed by PCR from two
different plasmids encoding the parental HAs; following puriﬁcation of fragments, a Gibson assembly reaction is set up to obtain
a cHA.
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Fig. 2. NEBuilder Assembly Tool preferences.
F. Ferrara, N. Temperton /MethodsX 4 (2017) 11–24 15[47_TD$DIFF][(Fig._3)TD$FIG]Copy in the box the complete nucleotide sequence of the parental 2HA,which is the one fromwhich
the stalk region is taken, name it (STALK), and select “Make this the vector backbone” as shown in
Fig. 3. Press “CONTINUE”.
[48_TD$DIFF] In “Vector backbone will be linearized” sub-section select “PCR” as shown in Fig. 4.
[49_TD$DIFF] In ‘Deﬁne the position of the insert sitewithin the vector’ sub-section select “By Sequence Position”
as shown in Fig. 4.
[50_TD$DIFF] Now insert in the “Upstream ﬂanking base” and “downstream ﬂanking base” sub-sections the
numbers previously identiﬁed in step V above. Then press “DONE”.
[51_TD$DIFF] Press “ADD FRAGMENT” and copy the nucleotide sequence of the parental 1 HA head. Remember to
name the sequence (HEAD) as shown in Fig. 5, and then press “CONTINUE”.
[52_TD$DIFF] In “Insert DNAwill be produced by” sub-section select “PCR” as shown in Fig. 6. Leave all the other
values untouched and then press “DONE”.
[53_TD$DIFF] The tool will automatically design the primers and additionally advise on the annealing
temperature to use as shown in Fig. 7. The software also provides the assembled sequence, thatFig. 3. Entry of the parental 2 HA (stalk donor) sequence.
[(Fig._4)TD$FIG]
Fig. 4. Preferences to be set for parental 2 HA (stalk donor) sequence.
[(Fig._5)TD$FIG]
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designed in step IV.
[54_TD$DIFF] Primers can be ordered from a range of commercial suppliers desalted and at 25nm scale or lower.
Step 2: PCR
PCR of the head fragment and of the stalk plus vector fragment should be performed following the
manufacture’s instruction using Q51 High-Fidelity DNA Polymerase. We routinely perform minor
changes, such as increasing the denaturation/annealing and extension times. In Tables 1 and 2, theFig. 5. Entry of the parental 1 HA (head donor) sequence.
[(Fig._6)TD$FIG]
Fig. 6. Preferences to be set for parental 1 HA (head donor) sequence.
[(Fig._7)TD$FIG]
Fig. 7. Example of designed primers.
Oligonucleotide sequences to be ordered are reported in the table with information about the regions that they anneal to, and
the Annealing Temperature (30Ta) that should be used in the PCR to amplify the stalk plus vector and the head fragments.
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Table 1
PCR program for the ampliﬁcation of HA stalk plus vector.
Cycles Temperature Time Step
98 C 3min Initial denaturation
30 cycles 98 C 30 s Denaturation
Recommended Primer Annealing Temperature 30 s Annealing
72 C 6min Extension
72 C 8min Final extension
4 C To preserve reactions until removed
Table 2
PCR program for the ampliﬁcation of the HA head.
Cycles Temperature Time Step
98 C 3min Initial denaturation
30 cycles 98 C 15 s Denaturation
Recommended Primer Annealing Temperature 30 s Annealing
72 C 1min Extension
72 C 2min Final extension
4 C To preserve reactions until removed
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are reported.
Step 3: Analytical gel electrophoresis
5ml of PCR reaction should be run on a 0.7–1% agarose gel to conﬁrm the ampliﬁcation of the stalk
plus vector and of the head region (Fig. 8). To correctly perform agarose gel electrophoresis we
recommend consulting “Molecular Cloning: A Laboratory Manual” [7].
Note: if preferred the two PCR reactions can be run on a preparative gel to then proceed to gel
extraction of the DNA bands corresponding to fragments ampliﬁed. In this case STEP 4–6 are not
required. We do not use gel extraction, as in our hands using commercial kits, the efﬁciency of gel
extraction is lower than PCR puriﬁcation.
Step 4: PCR puriﬁcation
When the ampliﬁcation of the target DNA has been conﬁrmed, the PCR reaction must be puriﬁed
before proceeding to additional steps (e.g. DpnI digestion or Gibson Assembly). QIAquick PCR
Puriﬁcation Kit (QIAGEN) or similar can be used for this purpose. DNA concentration should be
measured using Nanodrop instruments or a spectrophotometer.
Parental DNA digestion using DpnI (recommended)
To increase Gibson Assembly efﬁciency and reduce background from residual template DNA,
restriction enzyme digestion usingDpnI can be performed.DpnI is a restriction enzyme that can cleave
DNA at a speciﬁc site (GATC), but only if this is methylated or hemimethylated. This permits the
degradation of plasmid template DNA isolated from dam+ E. coli strains but not of the ampliﬁed PCR
products. FastDigest1 DpnI can be used following the manufacturer’s instructions. Routinely 400–
600ng of puriﬁed PCR reaction is digested in a total volume of 10–20ml (depending on the DNA
concentration) using 1ml of enzyme (10U). The digestion reaction is performed for 15min at 37 C in a
water bath or ideally in a heating block pre-set to 37 C. Subsequently the reactions should be puriﬁed
to remove buffer salts and enzymes and for subsequent use in the Gibson assembly reaction.
[(Fig._8)TD$FIG]
Fig. 8. Ampliﬁcation of HA stalk plus vector and HA head.
In the agarose gel, two bands corresponding to the ampliﬁed product of the HA stalk plus vector of phCMV1-A/South Carolina/1/
1918 H1 and of the HA head of phCMV1-A/duck/Memphis/546/1974 H11 can be observed.
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Gibson assembly must be performed following manufacturer’s instructions: the reaction is
performed in a 20ml total volume inwhich 10ml Gibson Assembly Master Mix, vector and insert, and
DNase and RNAse are added. Good results have been obtained using a vector (HA stalk plus vector):
insert (HA head) ratio 1:3. For example, for a HA stalk plus vector of 5.3Kb and a head fragment of
700bp, 80ng of HA stalk plus vector, and 29ng HA head should be used in the reaction. The Gibson
assembly reaction should be incubated for 15min at 50 C, before proceeding to bacterial
transformation following manufacturer’s instructions.
Step 7: Colony [55_TD$DIFF]PCR screening (optional)
If numerous colonies are present on the plate of the transformed Gibson assembly reaction, it is
possible to perform colony PCRs to simultaneously screen more clones for the presence of the
assembled corrected HA. For this purpose vector speciﬁc primers or gene speciﬁc primers can be used.
Vector speciﬁc primers should anneal upstream and downstream of the cHA gene and they can
potentially amplify the parental HA (especially the parental stalk HA since its encoding plasmid is
always the same as the cHA) if the DpnI digestionwas not performed correctly. Gene speciﬁc primers
can be designed as an alternative: one should anneal the cHA stalk, and the other the cHA head.
Primers used for ampliﬁcation of the HA head can also be used, but will result in less informative
screening (since it is possible to amplify the parental HA, if its encoding plasmid was not correctly
Table 3
Colony PCR program.
Cycles Temperature Time Step
94 C 2min Initial denaturation
30 cycles 94 C 30 s Denaturation
Depending on Primers’ Annealing Temperature 1min Annealing
72 C 2min Extension
72 C 5min Final extension
4 C To preserve reactions until removed
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numbered correctly to be able to identify positive clones.
Colony PCR can be performed as follows.i A PCR stock mix can be prepared by considering the number of samples to be screened and for
each reaction adding 12.5 ml of DreamTaq Green PCR Master Mix, 0.1 ml of each Fwd and Rev
primers (ﬁnal concentration 400 nM).ii Subsequently the PCR stock mix should be aliquoted into PCR microtubes (20 ml in each tube).
iii Alongside the PCR stock mix preparation, each bacterial colony to be tested should be numbered
and diluted in 20ml of DNase/RNase free water before streaking the colony onto a numbered grid
previously prepared on an appropriate LB Agar plate.iv Negative (colony with empty vector) and positive (colony with vector and insert) controls are
inserted if available.v An additional control consisting of DNase/RNase freewater can be added to evaluate if carry-over
of DNA was present during the procedure.vi After a lysis step at 94 C for 3min in a thermal cycler, 5ml of each colony suspension is transferred
to a numbered PCR microtube in which 20 ml of PCR mix is already present.vii Tubes should be positioned in a thermocycler and the colony PCR program detailed in Table 3
should be run.viii Ampliﬁcation of the target sequence should be veriﬁed through analytical DNA gel
electrophoresis. If DreamTaq Green PCR Master Mix was used samples can be directly loaded
on an agarose gel.If vector speciﬁc primers were used the positive clones to be further analysed are the ones inwhich
a 1.7 Kbp band is present after analytical DNA gel electrophoresis. For gene speciﬁc primers the length
of the band will be dependent on the position of the primer used. If primers annealing to stalk and
head of the cHAwere used, ampliﬁcation should be observed only for the clones inwhich the cHAwas
correctly assembled. Positive colonies from the plate streaked during the colony PCR can be selected
for further analysis in step 8.
Step 8: Isolation of plasmid dna
(Positive) colonies resulting from bacterial transformation of the Gibson assembly reaction should
be inoculated and plasmid DNA should be isolated using QIAprep Spin Miniprep Kit following
manufacturer’s instructions.
Step 9: Screening with restriction enzymes and [56_TD$DIFF]Sanger sequencing
This step is technically demanding: it is necessary to identify single, or a couple of restriction
enzymes that cleave with differential patterns the two parental HAs and the newly generated cHA
plasmids. Where possible full plasmid sequence should be analysed but, if not available, the analysis
can be performed using HA sequences, the empty plasmid sequence, and the enzyme sites used for the
original cloning. To identify the enzymes, software such as DNADynamo that permits virtual digestion
of sequences can be used to test different enzyme combinations and calculate the size of the DNA
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patterns observed after electrophoresis should be analysed for the two parental HAs and the newly
generated cHA plasmids. Once the appropriate restriction enzymes are identiﬁed, plasmid clones
should be digested. Plasmid DNA digestions of the Gibson assembly reaction clones and of the two
parental HAs should be performed following the manufacturer’s instructions of the restriction
enzyme used. The use of FastDigestTM enzymes using the FastDigestTM Green Buffer for direct loading
on gels is recommended. Usually 600ng of DNA and a 15min incubation at 37 C can be used for
optimal results. Reactions directly loaded on a 1% agarose gel can be subjected to gel electrophoresis
using TAE buffer. Undigested plasmid, especially of the parental HA, should also be added as control in
the gel electrophoresis. After running the gel at an appropriate voltage and for an appropriate amount
of time, the gel should be visualized using a gel doc system and the bands should be identiﬁed. Clones
that show a digestion pattern ascribable to cHA should be subjected to Sanger sequencing using
primers that anneal to the vector upstream and downstream of the cHA gene for ﬁnal conﬁrmation.
Step 10: Sequence identiﬁcation
Amino acid identity of the cHA constructwith the theoretical amino acid sequence generated using
the NEBuilder Assembly Tool should be veriﬁed after Sanger sequencing of the selected clones before
using the constructs for further applications. The assembled sequence is generally correct, however
single point mutations (probably introduced during PCR) can be observed in certain clones.
Pseudotype particle production
Lentiviral or retroviral pseudotypes harbouring the cHA with different vector proﬁles can be
produced depending on the core proteins and genome expressing plasmid selected. Some further
points that should be considered before performing production or optimization of pseudotypes are
presented below.[26_TD$DIFF] If the stalk of a highly pathogenic avian inﬂuenza haemagglutinin (H5 or H7), which possess a
multibasic cleavage site, was used to generate the cHA it is possible to produce pseudotype
particles as previously described [8,9] using a transfection DNA mix containing a lentiviral (or
retroviral) vector and a packaging system (or pNL4.3), and the cHA encoding plasmid.[57_TD$DIFF] Alternatively, if the stalk originates from a human (seasonal) or a low pathogenic avian inﬂuenza
haemagglutinin, possessing a single arginine at the cleavage site, a protease-encoding plasmid
should be added to the transfectionmix. As previously reported, it is necessary to optimize quantity
and type of proteases used.
[58_TD$DIFF]Note: It has been observed that the cleavage conditions used to produce pseudotype particles
harbouring cHAs do not correspond to the cleavage conditions of the parental HA that has donated the
stalk and it is not yet possible to predict the conditions that need to be used (Fig. 9).[59_TD$DIFF][60_TD$DIFF] Additional and concurrent optimizations of the quantity of the HA plasmid transfected for
production of pseudotypes can also be necessary in certain cases. Exogenous neuraminidase (Sigma-Aldrich or Roche) should be added to facilitate pseudotype
release 24h post-transfection. Alternatively, a neuraminidase encoding plasmid can be added to the
transfection mix.
A protease encoding plasmid is added to the transfection mix to enable HA activation when the
parental HA used for the stalk posseses a monobasic cleavage site. Different types of proteases and
different quantities of plasmids need to be tested to obtain higher titre pseudotype particles.
Pseudotypes produced in absence of a protease-encoding plasmid should be used as controls. These
pseudotypes can also be activated using TPCK-trypsin.A.As an example the production titres obtained
for a cHAwith H1 stalk and H11 head are reported. B. Comparison between the activiation proﬁles of
[(Fig._9)TD$FIG]
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Fig. 9. Production of chimeric haemagglutinin pseudotypes.
22 F. Ferrara, N. Temperton /MethodsX 4 (2017) 11–24pseudotype with cHA (H1 stalk and H11 head) or the parental HAs: the darker color indicates higher
titer.
Pseudotype neutralization assay
A cHA pseudotype neutralization assay should be performed as previously reported [11]. Data can
be analysed to calculate the half maximal inhibitory concentration (IC50) using statistical software
such as Graphpad Prism or Microsoft Excel. Since the presence of homosubtypic and heterosubtypic
antibodies against head epitopes cannot be excluded (since monoclonal antibodies with this activity
have been isolated) additional controls should be introduced: assays using pseudotypes harbouring
each of the parental HAs must be performed in parallel. This permits a holistic and comprehensive
interpretation of the data and of the IC50 results.
Results can be interpreted following the following rationale: Stalk-directed responses are present if the antibody titre obtained against the cHA is greater than the
titre against the parental head HA. In fact, increases in antibody titres are detected since with the
cHA a conserved stalk epitope is introduced. If the titres against the cHA are lower than the ones against the stalk parental HA, cross-reactive
antibody directed against the HA head are present. In other words, the presence of the stalk epitope
does not explain the antibody titres observed using the stalk parental HA.
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Protein folding
It has been observed that it is difﬁcult to evaluate and predict if the cHA created will have correct
folding or will be efﬁciently expressed, especially if highly divergent stalk and head regions are used.
For this reason, if viable pseudotypes cannot be produced, the expression of the cHA should be
evaluated using immunoﬂuorescence and/or SDS-PAGE and Western Blotting.
Epitopes at the hinge of stalk and head regions
While enabling the identiﬁcation of antibodies against the HA stalk, cHAs canprevent the detection
of antibodies directed against epitopes situated between the head and the stalk regions. These
epitopes may have some potential for cross-neutralization. This should be taken into consideration
when data and IC50 results are interpreted. Furthermore, it cannot be excluded that this newly
constituted hinge region generates a new epitope, which may or may not be recognised in
neutralization assays.
Flexibility
The method described permits the simple cloning of cHAs possessing the same stalk but different
heads. In fact, during primer design overlapping sequences are inserted on the head fragments. For
this reason, the same HA stalk plus vector can be used for multiple reactions. This could be an
important advantage considering that the current pre-clinical vaccination strategy using cHAs
consists of the immunisation of different cHAs that possess different heads but have common stalks
[10]. The H11/H1 chimeric HA pseudotype described in Fig. 9 has been used recently by us tomeasure
the neutralizing antibody response directed against the H1 stalk elicited by a novel dissolvable
microneedle vaccine [11]. Additionally, the Gibson assembly cloning procedure that we have reported
could be used with appropriate modiﬁcation by other investigators to evaluate chimeric proteins. The
method is extremely useful when small or medium portions of a protein, such as single epitopes or
domains, need to be modiﬁed: in fact mutagenesis techniques are often not efﬁcient and usually
appropriate restriction enzyme sites to proceed with a traditional cloning step are not available.
Furthermore, by adding additional sequences during the primer design and the PCR step (or through
gene synthesis of a fragment in which overlapping sequence resulting from the primer design were
added) it is possible to create fusion proteinswhen linker regionswith appropriate restriction enzyme
sites are not available.
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